Overcoming Resistance in
Malignant Brain Cancer
First-in-class inhibitor of calcium signaling targeting glioblastoma and resistant solid tumors
Tactical Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies designed to penetrate the brain and overcome resistance in the most aggressive cancers.
One Step Ahead
Advancing Breakthrough Therapies for the Most Challenging Cancers
Tactical Therapeutics is focused on the development of a patented therapeutic platform targeting glioblastoma (GBM) and other resistant solid tumors. The company’s lead compound, Carboxyamidotriazole Orotate (CTO), is an oral, brain-penetrant therapy designed to inhibit calcium signaling pathways associated with multiple oncogenic mechanisms.
Our mission is to overcome therapeutic resistance in cancers where current treatments fall short, bringing new hope to patients facing devastating diagnoses.
Tactical Therapeutics
A Novel Approach to Targeting Cancer Resistance
Our lead therapeutic, CTO, is a first-in-class and best-in-class inhibitor of non-voltage-dependent calcium (ca)²⁺ signaling, impacting multiple oncogenic pathways simultaneously.
Oral therapy with strong safety profile
Crosses the blood-brain barrier effectively
Targets multiple cancer pathways
Designed to overcome resistance mechanisms
Tactical Therapeutics
Meet The Founder, CEO, Board Member & President
Rashida A. Karmali, Ph. D, JD, MBA
three steps to success
Promising Clinical Outcomes in Difficult-to-Treat Patients
Clinical trials of CTO have demonstrated encouraging results in patients with advanced and recurrent glioblastoma:
Complete and partial responses observed in heavily pretreated patients
69% two-year survival rate
93% one-year survival rate
Long-term recurrence-free survivors reported
Building the Future of Oncology Therapeutics
Tactical Therapeutics is advancing its clinical program through early-phase trials and preparing for Phase II development in glioblastoma and other solid tumors.
Early-phase oncology trial execution
Pharmacokinetics and tissue penetration studies
Biomarker-driven translational research
Imaging-based response assessment
Preclinical and clinical integration strategies
Partner With Us
Partnering to Transform Cancer Treatment
Tactical Therapeutics is actively seeking strategic partners to advance development and commercialization of CTO and related therapies.
We collaborate with leading researchers, clinicians, and organizations committed to improving outcomes for patients with glioblastoma and resistant cancers.